Highly Selective News Today

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 -- HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new...

Investegate announcements from HUTCHMED Data to be Presented at EHA2024 Congress

In response to the Supreme Court's affirmative action ruling, colleges are expanding financial aid, boosting socioeconomic diversity efforts. Read to learn more.

An app called Blinkist costs $12.99 a month and is designed to help you achieve your New Year resolution to “read” more books. Blinkist offers brief summaries that give the

'Safety profile is one of the real advantages' of non-covalent BTK inhibitor, says panelist

/PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at...

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose  Nearly all patients achieved at...

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose

Back pain can stop you from getting things done throughout the day. Read our article for the best CBD oil for back pain in 2023!

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Brutons tyrosine kinase...